Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OTLK Outlook Therapeutics, Inc.

Trading 02-27 12:06:36 EST

0.4294

-0.0039

-0.90%

High0.4377	Low0.4200	Vol278.26K
Open0.4200	D1 Closing0.4333	Amplitude4.08%
Mkt Cap35.67M	Tradable Cap29.08M	Total Shares83.07M
T/O119.23K	T/O Rate0.41%	Tradable Shares67.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OTLK","market":"US","secType":"STK","nameCN":"Outlook Therapeutics, Inc.","latestPrice":0.4294,"timestamp":1772211926807,"preClose":0.4333,"halted":0,"volume":278264,"delay":0,"changeRate":-0.009000692360950876,"floatShares":67733200,"shares":83067200,"eps":-2.89,"marketStatus":"Trading","change":-0.0039,"latestTime":"02-27 12:06:36 EST","open":0.42,"high":0.4377,"low":0.42,"amount":119225.78092712001,"amplitude":0.040849,"askPrice":0.4334,"askSize":600,"bidPrice":0.4226,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-2.89,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772226000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.4333,"preHourTrading":{"tag":"盘前","latestPrice":0.428,"preClose":0.4333,"latestTime":"08:52 EST","volume":11771,"amount":5074.34908984,"timestamp":1772200357468,"change":-0.0053,"changeRate":-0.012232,"amplitude":0.053081},"postHourTrading":{"tag":"盘后","latestPrice":0.44,"preClose":0.4333,"latestTime":"19:27 EST","volume":9638,"amount":4234.2019,"timestamp":1772152069515,"change":0.0067,"changeRate":0.015463,"amplitude":0.02931},"volumeRatio":0.779075,"impliedVol":2.2354,"impliedVolPercentile":0.757},"requestUrl":"/m/hq/s/OTLK/wiki","defaultTab":"wiki","newsList":[{"id":"2612283168","title":"Outlook enters distribution agreement for sale of Lytenava in Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2612283168","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612283168?lang=en_us&edition=fundamental","pubTime":"2026-02-19 22:16","pubTimestamp":1771510565,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) announced they have entered into an exclusive commercial distribution agreement for the sale and distribution of Lytena...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-enters-distribution-agreement-for-sale-of-lytenava-in-switzerland-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-enters-distribution-agreement-for-sale-of-lytenava-in-switzerland-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2612288254","title":"Outlook Therapeutics Signs Exclusive LYTENAVA Distribution Agreement With Mediconsult AG in Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2612288254","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612288254?lang=en_us&edition=fundamental","pubTime":"2026-02-19 22:00","pubTimestamp":1771509642,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc. signed an exclusive commercial distribution agreement with Mediconsult AG for LYTENAVA  in Switzerland. Mediconsult will have exclusive rights to market, import, distribute and commercialize the product and will handle Swiss regulatory activities, including seeking and maintaining marketing authorization, while Outlook Therapeutics will remain responsible for manufacturing, product supply and related intellectual property. The companies said LYTENAVA is expected to be available in Switzerland in 2027, subject to marketing authorization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 19, 2026","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL7QqD7g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","OTLK","LU0314104364.USD","SG9999014005.SGD","SG9999014021.USD","IE00BGHQF748.EUR","BK4588","SG9999014013.SGD","LU2210150020.SGD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","BK4585","BK4139","LU2095319765.USD","SG9999014039.USD","NDAQ"],"gpt_icon":0},{"id":"2612882272","title":"Outlook Therapeutics: Partnership Advances European Commercial Expansion Strategy, With Lytenava Expected to Launch in Switzerland in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2612882272","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612882272?lang=en_us&edition=fundamental","pubTime":"2026-02-19 22:00","pubTimestamp":1771509608,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA6FBQXM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2612428824","title":"Outlook Therapeutics Inc - Mediconsult to Market and Distribute Lytenava in Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2612428824","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612428824?lang=en_us&edition=fundamental","pubTime":"2026-02-19 22:00","pubTimestamp":1771509608,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA6FBQXM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2612028826","title":"Outlook Therapeutics Expands European Footprint With Exclusive Commercial Distribution Agreement With Mediconsult Ag for Lytenava™ (Bevacizumab Gamma) in Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2612028826","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612028826?lang=en_us&edition=fundamental","pubTime":"2026-02-19 22:00","pubTimestamp":1771509608,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA6FBQXM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2612422838","title":"Nasdaq Warns Outlook Therapeutics of Delisting Risk After Sub-$1 Share Price Streak","url":"https://stock-news.laohu8.com/highlight/detail?id=2612422838","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612422838?lang=en_us&edition=fundamental","pubTime":"2026-02-19 06:02","pubTimestamp":1771452136,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics said it received a Nasdaq notice that its shares have traded below the $1.00 minimum bid price requirement for 30 consecutive business days, putting it out of compliance with Nasdaq Listing Rule 5550. The company has until Aug. 17, 2026 to regain compliance by maintaining a closing bid price of at least $1.00 for at least 10 consecutive business days, or it could face delisting if it cannot cure the deficiency or qualify for an additional compliance period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commiss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL54rRtZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2612176452","title":"BRIEF-Outlook Therapeutics Q1 EPS USD -0.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2612176452","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612176452?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:05","pubTimestamp":1771333546,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Q1 EPS USD -0.38\n\n\nFeb 17 (Reuters) - Outlook Therapeutics Q1 adjusted EPS USD -0.22.\n\nQ1 net income USD -23.1 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nPLXE4852C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2612436452","title":"Outlook Therapeutics posts Q1 net income of USD -23.1 million, swinging from profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2612436452","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612436452?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:05","pubTimestamp":1771333532,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc. reported a net loss attributable to common stockholders of USD 23.1 million, or USD 0.38 per basic and diluted share, for the fiscal first quarter ended December 31, 2025, compared to net income of USD 17.4 million for the same period last year. The company posted an adjusted net loss attributable to common stockholders of USD 13.5 million, or USD 0.22 per basic and diluted share, for the quarter. Adjusted net loss excludes USD 6.7 million related to loss from change in fair value. The company highlighted ongoing regulatory processes for ONS-5010 and cited macroeconomic risks, including overseas conflicts and inflation, as factors that could impact future performance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal adv","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDLc2b1fq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","LU2095319765.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014021.USD","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","IE00B64PRP62.GBP","BK4112","IE00BGHQF748.EUR","OTLK","LU2210149790.SGD","SG9999014039.USD","LU0314104364.USD","BK4585"],"gpt_icon":0},{"id":"2612452175","title":"Outlook Therapeutics Q1 Net Income USD -23.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2612452175","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612452175?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:05","pubTimestamp":1771333501,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nPLXE4852C:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2612524334","title":"Press Release: Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2612524334","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612524334?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:05","pubTimestamp":1771333500,"startTime":"0","endTime":"0","summary":"underway, including commercial launch in Austria in January 2026. \"LYTENAVA  is demonstrating increasing adoption in Europe following our initial launches, with growing demand and quarter-over-quarter unit sales growth,\" said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. \"Building on this momentum, we are actively working towards launching into additional EU markets in the near term, following our January launch into Austria, as part of a broader regional expansion strategy.\". In addition to the planned launches of LYTENAVA in Ireland and the Netherlands in 2026, followed by France, Italy and Spain in 2027, Outlook Therapeutics also continues with its efforts to potentially partner with established companies in other countries in Europe, Latin America and Asia.Revenue in the fiscal quarter ended December 31, 2025 was negatively impacted by an increase in the returns reserve for estimated product returns from the UK distributor resulting from short dated product used for th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMDD","LU0757428866.USD","LU0198837287.USD","AMYY","LU0979878070.USD","LU0642271901.SGD","LU1988902786.USD","LU2098885051.SGD","BK4539","LU0056508442.USD","BK4612","LU0109392836.USD","LU0029874061.USD","LU2360106780.USD","AMDG","LU0719512351.SGD","LU2089985449.USD","LU2458330243.SGD","AMDY","BK4575","LU1242518857.USD","BK4121","LU1880398471.USD","LU0128526141.USD","LU2264538146.SGD","BK4573","LU1064131342.USD","BK4614","IE00BFMHRM44.USD","LU0082616367.USD","BK4530","BK4588","LU0081259029.USD","LU2931357623.SGD","LU1316542783.SGD","LU1951198990.SGD","LU0823421416.USD","IE00BMPRXR70.SGD","BK4532","AMDU","BK4534","LU0127658192.USD","IE0009356076.USD","BK4604","LU1242518931.SGD","BK4007","BK4605","LU0274383776.USD","LU0823434740.USD","LU1803068979.SGD","LU1303367103.USD","IE00B5949003.HKD","BK4099","LU1951200564.SGD","LU0889565833.HKD","LU1989764664.SGD","BK4554","LU1861559042.SGD","LU0390134368.USD","LU2355687059.USD","AMUU","LU1880398554.USD","LU1852331112.SGD","LU2054465674.USD","BK4512","BK4139","DAMD","LU2458330169.SGD","BK4141","LU1861558580.USD","LU2250418816.HKD","BK4585","OTLK","IE0004445239.USD","BK4543","BK4555","LU1815336091.USD","LU1923623000.USD","BK4529","BK4566","LU0823434583.USD","AMDW","03160","IE00BMPRXN33.USD","LU0823421333.USD"],"gpt_icon":1},{"id":"2610680953","title":"Outlook Therapeutics sumbits Type A meeting request to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2610680953","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610680953?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:50","pubTimestamp":1770817819,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) submitted a Type A meeting request to the U.S. Food and Drug Administration following receipt of a Complete Response Le...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-sumbits-type-a-meeting-request-to-fda-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-sumbits-type-a-meeting-request-to-fda-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","OTLK","BK4539","LENZ","BK4139"],"gpt_icon":0},{"id":"2610695870","title":"Outlook Therapeutics Inc: Intends to Continue to Work With FDA on a Path Forward for Resolving FDA's Request for Additional Confirmatory Evidence","url":"https://stock-news.laohu8.com/highlight/detail?id=2610695870","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610695870?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:45","pubTimestamp":1770817500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA812VQ1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2610587359","title":"Outlook Therapeutics Submits Type a Meeting Request to FDA Following Complete Response Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2610587359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610587359?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:45","pubTimestamp":1770817500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA812VQ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2606221891","title":"Outlook Therapeutics Inc. Announces Date for Upcoming Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2606221891","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606221891?lang=en_us&edition=fundamental","pubTime":"2026-01-27 06:02","pubTimestamp":1769464948,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc. will hold its 2026 Annual Meeting of Stockholders on March 10, 2026. During the meeting, stockholders will vote on the election of three directors, the ratification of the selection of KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending September 30, 2026, and a non-binding advisory vote on the compensation of Outlook Therapeutics’ named executive officers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 26, 2026, and is solely responsib","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL2gBC5F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2601909978","title":"Press Release: Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2601909978","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601909978?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:35","pubTimestamp":1767706500,"startTime":"0","endTime":"0","summary":"ISELIN, N.J., Jan. 06, 2026  -- Outlook Therapeutics, Inc. , a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development.\"We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution,\" said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. \"Laura's two decades of global biotechnology experience spanning corporate strategy, business development and portfolio leadership, and her proven ability to identify, evaluate and execute high-value opportunities, will be instrumental as we advance our mission to deliver a differentiated ophthalmic formulation of bevacizumab and pursue opportunities to maximize long-term shareholder value.\". In her role as Vice President of Corporate Strategy and Business Development, Ms. Cantrell will be responsible for leading Outlook Therape","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTYY","IE0009356076.USD","3LMI.UK","BK4543","03160","MSTW","APED","LU0889565833.HKD","LMI3.UK","LU2250418816.HKD","SMST","LU1951200564.SGD","LENZ","MSST","MSDD","WNTR","MST","MSTK","MSTZ","BK4139","MSTX","BK4099","MSII","MSTY.UK","SMI3.UK","LU1064131342.USD","07399","3SMI.UK","MSTP","LU1803068979.SGD","07799","IMST","MSOO","09399","OTLK","BK4023","LU1242518931.SGD","LU1951198990.SGD","MSTY","TM","LU0979878070.USD","LU1316542783.SGD","09799","LU1242518857.USD","LU1880398471.USD","BK4595","BK4585"],"gpt_icon":1},{"id":"2600067611","title":"Sector Update: Health Care Stocks Mixed in Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2600067611","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600067611?lang=en_us&edition=fundamental","pubTime":"2026-01-03 02:50","pubTimestamp":1767379803,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed Friday afternoon, with the NYSE Health Care Index fractionally higher and the State Street Health Care Select Sector SPDR ETF  easing 0.1%.The iShares Biotechnology ETF  was down 0.6%.In corporate news, Ironwood Pharmaceuticals  shares jumped 29% after the company said it expects sales of its irritable bowel syndrome with constipation or chronic constipation treatment, Linzess, in the US to be higher this year compared with 2025.Outlook Therapeutics  shares fell 58% after the company said Wednesday the US Food and Drug Administration has issued a complete response letter for its ONS-5010 biologics license application resubmission.Hoth Therapeutics  shares climbed 4.4% after it said Friday it has filed two US provisional patent applications aimed at expanding its intellectual property portfolio and establishing an oncology-focused dermatology platform.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4581","OTLK","XBI","IRWD","BK4585","BK4007","IBB","LABU","HOTH","XLV","BK4588"],"gpt_icon":0},{"id":"2600064912","title":"Crude Oil Falls 1%; US Manufacturing Growth Eases In December","url":"https://stock-news.laohu8.com/highlight/detail?id=2600064912","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600064912?lang=en_us&edition=fundamental","pubTime":"2026-01-03 01:13","pubTimestamp":1767374029,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/26/01/49671500/crude-oil-falls-1-us-manufacturing-growth-eases-in-december","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNQmain","SQQQ","CHOW","BK4139","UAVS","BK4152","QID","TQQQ","BK4603","USAW.SI","BK4082","OTLK","USJW.SI","TSYW.SI","QLD","NQmain","NVIW.SI","SELX","PSQ","IRWD","BK4134","BK4141",".IXIC"],"gpt_icon":1},{"id":"2600618880","title":"BUZZ-U.S. STOCKS ON THE MOVE-Rivian, Tesla, MGM Resorts","url":"https://stock-news.laohu8.com/highlight/detail?id=2600618880","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600618880?lang=en_us&edition=fundamental","pubTime":"2026-01-02 23:42","pubTimestamp":1767368536,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Rivian, Tesla, MGM ResortsEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:/","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nL6N3Y30DT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","WSM","LU0426412945.USD","SCCO","LU0011850046.USD","RIO.AU","RIO.UK","KVYO","IE00BQXX3C00.GBP","TSLA","IE00BK4W5L77.USD","WDAY","IRWD","CMG","HK0000320223.HKD","RIVN","LU0127658192.USD","89888","AP","CDE","LASE","RAMP","RH","LU1366333091.USD","RBOT","BK4592","BK4161","LU0055631609.USD","LU1883866441.USD","NEM","INTU","W","MGM","TSYW.SI","LU0061474960.USD","ESHA","LU0029864427.USD","BHP.AU","HL","OTLK","BK4596","IE00B894F039.SGD"],"gpt_icon":1},{"id":"2600065801","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2600065801","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600065801?lang=en_us&edition=fundamental","pubTime":"2026-01-02 21:08","pubTimestamp":1767359318,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) shares were down 61% in recent Friday premarket activity, after the company said Wednesday the US Food and Drug Administration has issued a complete response letter to the ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4202","FMFC","BK4082","BK4139","NVVE","OTLK","BK4096"],"gpt_icon":1},{"id":"2600306331","title":"BUZZ-U.S. STOCKS ON THE MOVE-Silver and gold miners, Baidu, Outlook Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2600306331","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600306331?lang=en_us&edition=fundamental","pubTime":"2026-01-02 20:21","pubTimestamp":1767356491,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Silver and gold miners, Baidu, Outlook TherapeuticsEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nL6N3Y309M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4514","LU0300736492.USD","LU0173614495.USD","LU0345780281.USD","LU1280957306.USD","BK4548","LU1223082196.USD","BK4543","LU0640476718.USD","BK4532","SG9999001143.SGD","BK4017","LU0368265764.SGD","LU2498475776.HKD","BK4579","LU0278409577.USD","LU1883866441.USD","LU0654597011.USD","LU0266512473.USD","BK4210","LU0456854461.SGD","LU0612318385.USD","IE00B0JY6N72.USD","LU1223082519.USD","LU0612318971.USD","BK4587","LU0075056555.USD","EXK","LU1223083913.SGD","LU0724618789.USD","LU0498741114.HKD","LU1115378108.SGD","HL","BK4531","BK4602","LU1023057109.AUD","LU0266512127.USD","BIDU","LU0788108826.HKD","LU2462611646.USD","BK4574","LU0640798160.USD","LU0788109121.HKD","BK4139","LU0630314457.HKD","BK4535","LU0498741890.SGD","LU0055631609.USD","BK4504","LU0300736062.USD","BK4570","LU1430597077.USD","SBSW","LU0345781412.USD","GFI","NEM","BK4552","BK4614","LU0359201612.USD","BK4588","OTLK","09888","BK4533","LU0330918003.SGD","LU0287142896.SGD","LU0345780521.USD","BK4585","LU0496367417.USD","LU1023059493.AUD","BK4526","BK4077","CDE","LU0345780950.USD","SVM","BK4612","HMY","GOLD","LU0359202008.SGD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.outlooktherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.003},{"period":"1month","weight":-0.1285},{"period":"3month","weight":-0.7579},{"period":"6month","weight":-0.491},{"period":"1year","weight":-0.7111},{"period":"ytd","weight":-0.7258}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":-0.0089},{"period":"3month","weight":0.0086},{"period":"6month","weight":0.0686},{"period":"1year","weight":0.1594},{"period":"ytd","weight":0.0108}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.033268},{"month":2,"riseRate":0.4,"avgChangeRate":0.143065},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.049534},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.10242},{"month":5,"riseRate":0.666667,"avgChangeRate":0.154179},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.046947},{"month":7,"riseRate":0.6,"avgChangeRate":0.042124},{"month":8,"riseRate":0.3,"avgChangeRate":-0.178581},{"month":9,"riseRate":0.5,"avgChangeRate":0.048784},{"month":10,"riseRate":0.5,"avgChangeRate":0.176993},{"month":11,"riseRate":0.2,"avgChangeRate":-0.102562},{"month":12,"riseRate":0.3,"avgChangeRate":-0.107149}],"exchange":"NASDAQ","name":"Outlook Therapeutics, Inc.","nameEN":"Outlook Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Outlook Therapeutics, Inc.,OTLK,Outlook Therapeutics, Inc.股票,Outlook Therapeutics, Inc.股票老虎,Outlook Therapeutics, Inc.股票老虎国际,Outlook Therapeutics, Inc.行情,Outlook Therapeutics, Inc.股票行情,Outlook Therapeutics, Inc.股价,Outlook Therapeutics, Inc.股市,Outlook Therapeutics, Inc.股票价格,Outlook Therapeutics, Inc.股票交易,Outlook Therapeutics, Inc.股票购买,Outlook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}